| Literature DB >> 33703869 |
Viljami Salmela1, Lumikukka Socada1, John Söderholm1, Roope Heikkilä1, Jari Lahti1, Jesper Ekelund1, Erkki Isometsä1.
Abstract
Background: Previous studies have suggested that processing of visual contrast information could be altered in major depressive disorder. To clarify the changes at different levels of the visual hierarchy, we behaviourally measured contrast perception in 2 centre-surround conditions, assessing retinal and cortical processing.Entities:
Mesh:
Year: 2021 PMID: 33703869 PMCID: PMC8061742 DOI: 10.1503/jpn.200091
Source DB: PubMed Journal: J Psychiatry Neurosci ISSN: 1180-4882 Impact factor: 6.186
Fig. 1Brightness induction and contrast suppression tests. Top: Brightness induction refers to the effect of surround luminance on centre brightness (i.e., perceived luminance). The centre patches A and B are equal in luminance, but they appear different in brightness because of the difference in background luminance. A dark background enhances brightness; a bright background decreases brightness. Bottom: Contrast suppression refers to the effect of background on the apparent contrast of the centre. The centre patches C and D have identical contrast, but the contrast of C appears to be reduced or suppressed because of the collinear background. The contrasts of the backgrounds are identical, and only the orientation relative to the centre grating is different.
Participant characteristics
| Characteristic | Patients | Controls | |||
|---|---|---|---|---|---|
|
| |||||
| Total | Major depressive disorder | Bipolar disorder | Borderline personality disorder | ||
| Patients, | |||||
| Baseline | 111 | 46 | 38 | 27 | 29 |
| F/M | 74/37 | 27/19 | 27/11 | 20/7 | 21/8 |
| Follow-up | 74 | 33 | 24 | 17 | — |
| Sex | |||||
| χ2 | — | 3.75 | 0.60 | 0.37 | — |
| | — | 0.053 | 0.44 | 0.54 | — |
| Age, yr, mean ± SD | — | 31.8 ± 10.1 | 32.0 ± 9.3 | 28.0 ± 7.3 | 32.1 ± 9.0 |
| | — | — | |||
| | — | 0.76 | 0.83 | 0.11 | — |
| MADRS score, mean ± SD | — | 24.0 ± 6.2 | 21.7 ± 7.0 | 22.2 ± 6.5 | 2.3 ± 3.5 |
| | — | — | |||
| | — | < 0.001 | < 0.001 | < 0.001 | — |
| YMRS score, mean ± SD | — | 1.70 ± 2.66 | 3.44 ± 3.70 | 3.55 ± 2.62 | 0.74 ± 1.61 |
| | — | — | |||
| | — | 0.053 | < 0.001 | < 0.001 | — |
F = female; M = male; MADRS = Montgomery–Åsberg Depression Rating Scale; SD = standard deviation; YMRS = Young Mania Rating Scale.
χ2 test difference versus controls.
t test difference versus controls.
Fig. 2(A) We observed no difference in brightness induction between patients experiencing an MDE and controls (i.e., the perceptual difference between patches A and B in Figure 1 was similar for both groups). (B) We observed a highly significant difference in contrast suppression between patients experiencing an MDE and controls (i.e., the perceptual difference between patches C and D in Figure 1 was larger for controls than for patients). Error bars depict standard errors of the mean. MDE = major depressive episode.
Fig. 3Effect of (A) diagnostic subgroup and (B) medication on the strength of brightness induction (top) and contrast suppression (bottom). The error bars depict standard errors of the mean. BD = bipolar disorder; BPD = borderline personality disorder; MDD = major depressive disorder.
Medication use* in the patient group
| Medication | Subgroup (no. of patients) | Brightness induction | Contrast suppression | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Mood stabilizer (14) | Antipsychotic (21) | Antidepressant (78) | β | β | |||
| Valproate | 0.29 | 0.10 | 0.03 | 0.060 | 0.58 | −0.369 | 0.001 |
| Lamotrigine | 0.43 | 0.14 | 0.05 | 0.136 | 0.18 | −0.072 | 0.45 |
| Pregabalin | 0.29 | — | 0.05 | 0.054 | 0.63 | −0.076 | 0.47 |
| Benzodiazepine | 0.07 | 0.05 | 0.05 | 0.040 | 0.71 | 0.060 | 0.55 |
| SSRI, SARI or SMS | 0.36 | 0.43 | 0.68 | −0.103 | 0.35 | −0.092 | 0.37 |
| SNRI or tricyclic antidepressant | 0.36 | 0.14 | 0.32 | −0.001 | 0.99 | −0.036 | 0.75 |
| Tetracyclic antidepressant | 0.07 | — | 0.10 | −0.039 | 0.70 | −0.036 | 0.71 |
| NDRI | — | 0.05 | 0.06 | −0.032 | 0.75 | −0.027 | 0.78 |
| Agomelatine | — | — | 0.01 | −0.042 | 0.68 | −0.029 | 0.77 |
| Other | 0.07 | 0.05 | 0.03 | 0.023 | 0.82 | 0.116 | 0.24 |
NDRI = norepinephrine–dopamine reuptake inhibitor; SARI = serotonin antagonist and reuptake inhibitor; SMS = serotonin modulator and stimulator (vortioxetine); SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor.
Nineteen patients used no medication. Some patients used multiple medications.
Proportion of patients using the medication in each subgroup.
Brightness induction and contrast suppression β coefficients and p values are from linear regression analysis.
p < 0.01.
Fig. 4Follow-up results. The change in brightness induction (top) and contrast suppression (bottom) test scores at the end of follow-up plotted against the change in MADRS scores at the end of follow-up. MADRS = Montgomery–Åsberg Depression Rating Scale.